The issue with the Indian manufacturer, which continues to supply drug for other companies in the United States, was not related to Unicycive’s drug, the CEO said. But the agency hasn’t reinspected the plant in more than a year.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
